Mankind Pharma has entered a significant agreement with Takeda Pharmaceutical Company to introduce 'Vonoprazan' in the Indian market.
The company in a press statement on Tuesday said that the non-exclusive patent license agreement allows Mankind Pharma to commercialise Vonoprazan, a potassium-competitive acid blocker (P-CAB), for the treatment of Gastroesophageal Reflux Disease (GERD) and other acid-related disorders.
Vonoprazan is recognised for its efficacy in managing conditions such as erosive oesophagitis, gastric ulcer, peptic ulcer, and Helicobacter pylori eradication. This collaboration underscores Mankind Pharma's commitment to enhancing healthcare outcomes in India by offering innovative therapeutic options.
M Ramesh, EVP – Global Business Development at Mankind Pharma, highlighted the strategic importance of this partnership, stating, “This agreement with Takeda reinforces our dedication to introducing advanced treatments that cater to critical medical needs in India. Vonoprazan represents a new frontier in the management of acid-related illnesses, promising improved health outcomes and better quality of life for patients.”
